首页 > 最新文献

Revista Peruana de Medicina de Experimental y Salud Publica最新文献

英文 中文
First report of an acute case of chagas disease in the municipality of Miraflores, Guaviare, Colombia. 哥伦比亚瓜维亚雷州米拉弗洛雷斯市首例南美锥虫病急性病例报告。
Q3 Medicine Pub Date : 2024-08-19 DOI: 10.17843/rpmesp.2024.412.13271
José Ziadé Benítez, Diana Cedeño Díaz, Luz Alba Colorado, Laureano Mosquera Murillo, María Trinidad Orozco, Sandra Vallecilla, Julio Cesar Padilla, Mario J Olivera

We present a case of acute phase Chagas disease in a 40-year-old male patient from Vereda Buenos Aires, Municipality of Miraflores, Department of Guaviare. The patient attended the emergency department with fever, headache, asthenia, adynamia and dysuria. The blood smear and urinalysis were positive for symptomatic urinary tract infection, but negative for malaria. Five days later the diagnosis of acute phase Chagas disease was confirmed after a positive result for Trypanosoma cruzi. The patient was treated with nifurtimox and benznidazole, his contacts and risk areas were investigated, an active entomological community and institutional search was carried out, as well as in the reservoirs, finally, laboratory surveillance for possible cases of infection in the community was conducted. Five cases with similar symptoms were identified, but parasitological tests were negative. Health education measures were implemented to prevent the spread of the disease.

我们报告了一例来自瓜维亚雷省米拉弗洛雷斯市 Vereda Buenos Aires 的 40 岁男性南美锥虫病急性期患者。患者因发热、头痛、气喘、腺痛和排尿困难到急诊科就诊。经血涂片和尿液检查,症状性尿路感染呈阳性,但疟疾呈阴性。五天后,克鲁斯锥虫检测结果呈阳性,确诊为急性期恰加斯病。该患者接受了硝呋太保和苯并咪唑治疗,对其接触者和风险区域进行了调查,并在社区和机构以及蓄水池中进行了积极的昆虫学搜索,最后还对社区中可能的感染病例进行了实验室监测。发现了五例具有类似症状的病例,但寄生虫检测结果呈阴性。为防止疾病传播,采取了健康教育措施。
{"title":"First report of an acute case of chagas disease in the municipality of Miraflores, Guaviare, Colombia.","authors":"José Ziadé Benítez, Diana Cedeño Díaz, Luz Alba Colorado, Laureano Mosquera Murillo, María Trinidad Orozco, Sandra Vallecilla, Julio Cesar Padilla, Mario J Olivera","doi":"10.17843/rpmesp.2024.412.13271","DOIUrl":"10.17843/rpmesp.2024.412.13271","url":null,"abstract":"<p><p>We present a case of acute phase Chagas disease in a 40-year-old male patient from Vereda Buenos Aires, Municipality of Miraflores, Department of Guaviare. The patient attended the emergency department with fever, headache, asthenia, adynamia and dysuria. The blood smear and urinalysis were positive for symptomatic urinary tract infection, but negative for malaria. Five days later the diagnosis of acute phase Chagas disease was confirmed after a positive result for Trypanosoma cruzi. The patient was treated with nifurtimox and benznidazole, his contacts and risk areas were investigated, an active entomological community and institutional search was carried out, as well as in the reservoirs, finally, laboratory surveillance for possible cases of infection in the community was conducted. Five cases with similar symptoms were identified, but parasitological tests were negative. Health education measures were implemented to prevent the spread of the disease.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 2","pages":"203-208"},"PeriodicalIF":0.0,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resistance to cephalosporins and quinolones in Escherichia coli isolated from irrigation water from the Rímac river in east Lima, Peru. 从秘鲁利马东部 Rímac 河灌溉水中分离的大肠埃希菌对头孢菌素类和喹诺酮类药物的耐药性。
Q3 Medicine Pub Date : 2024-08-19 DOI: 10.17843/rpmesp.2024.412.13246
Mónica Huamán Iturrizaga, Gina Salvador-Luján, Liliana Morales, Jeanne Alba Luna, Lino Velasquez Garcia, Julio Daniel Pacheco Perez, Maria J Pons

Objectives.: To evaluate the presence and sensitivity to antimicrobials of Escherichia coli strains isolated from 24 irrigation water samples from the Rimac river of East Lima, Peru.

Materials and methods.: The E. coli strains were identified by PCR. Antibiotic susceptibility was processed by the disk diffusion method. Genes involved in extended spectrum beta-lactamases (BLEE), quinolones and virulence were determined by PCR.

Results.: All samples exceeded the acceptable limits established in the Environmental Quality Standards for vegetable irrigation. Of the 94 isolates, 72.3% showed resistance to at least one antibiotic, 24.5% were multidrug resistant (MDR) and 2.1% were extremely resistant. The highest percentages of resistance were observed for ampicillin-sulbactam (57.1%), nalidixic acid (50%), trimethoprim-sulfamethoxazole (35.5%) and ciprofloxacin (20.4%). Among the isolates, 3.2% had a BLEE phenotype related to the bla CTX-M-15 gene. qnrB (20.4%) was the most frequent transferable mechanism of resistance to quinolones, and 2.04% had qnrS. It was estimated that 5.3% were diarrheagenic E. coli and of these, 60% were enterotoxigenic E. coli, 20% were enteropathogenic E. coli and 20% were enteroaggregative E. coli.

Conclusions.: The results show the existence of diarrheogenic pathotypes in the water used for irrigation of fresh produce and highlight the presence of BLEE- and MDR-producing E. coli, demonstrating the role played by irrigation water in the dissemination of resistance genes in Peru.

Motivation for the study. Aquatic systems, including irrigation water, have been identified as reservoirs of antimicrobial resistance, with few studies in Peru on the presence of Escherichia coli and their levels of virulence and antimicrobial resistance. Main findings. Our results show the presence of E. coli above the established standard for vegetable irrigation water, some with very high levels of antimicrobial resistance. Implications. The presence of ESBL-producing strains of extended-spectrum beta-lactamases and multidrug-resistant E. coli in irrigation water could contribute to the dissemination of resistance genes in Peru, posing a significant threat to public health.

目的评估从秘鲁东利马 Rimac 河 24 个灌溉水样中分离出的大肠埃希氏菌株的存在情况和对抗菌剂的敏感性:通过 PCR 鉴定大肠杆菌菌株。抗生素敏感性采用盘扩散法进行处理。通过 PCR 测定涉及广谱β-内酰胺酶(BLEE)、喹诺酮类药物和毒力的基因:结果:所有样本都超过了蔬菜灌溉环境质量标准中规定的可接受限值。在 94 个分离菌株中,72.3% 的菌株对至少一种抗生素具有耐药性,24.5% 的菌株对多种药物具有耐药性,2.1% 的菌株具有极强的耐药性。耐药性百分比最高的是氨苄西林-舒巴坦(57.1%)、萘啶酸(50%)、三甲双氨-磺胺甲噁唑(35.5%)和环丙沙星(20.4%)。qnrB(20.4%)是最常见的喹诺酮类药物耐药性转移机制,2.04%具有qnrS耐药性。据估计,5.3%为致泻性大肠杆菌,其中 60%为肠毒性大肠杆菌,20%为肠致病性大肠杆菌,20%为肠聚集性大肠杆菌:结果表明,在用于灌溉新鲜农产品的水中存在致腹泻病原体,并突出显示了产生 BLEE 和 MDR 的大肠杆菌的存在,这表明灌溉水在秘鲁抗性基因的传播中发挥了作用。包括灌溉水在内的水生系统已被确定为抗菌药耐药性的储存库,但秘鲁对大肠杆菌的存在及其毒力和抗菌药耐药性水平的研究却很少。主要研究结果。我们的研究结果表明,蔬菜灌溉水中存在的大肠埃希氏菌超过了既定标准,其中一些大肠埃希氏菌具有很高的抗菌性。影响。灌溉水中存在产 ESBL 的广谱 beta 内酰胺酶菌株和耐多药大肠杆菌,可能会导致耐药基因在秘鲁传播,对公共卫生构成重大威胁。
{"title":"Resistance to cephalosporins and quinolones in Escherichia coli isolated from irrigation water from the Rímac river in east Lima, Peru.","authors":"Mónica Huamán Iturrizaga, Gina Salvador-Luján, Liliana Morales, Jeanne Alba Luna, Lino Velasquez Garcia, Julio Daniel Pacheco Perez, Maria J Pons","doi":"10.17843/rpmesp.2024.412.13246","DOIUrl":"10.17843/rpmesp.2024.412.13246","url":null,"abstract":"<p><strong>Objectives.: </strong>To evaluate the presence and sensitivity to antimicrobials of Escherichia coli strains isolated from 24 irrigation water samples from the Rimac river of East Lima, Peru.</p><p><strong>Materials and methods.: </strong>The E. coli strains were identified by PCR. Antibiotic susceptibility was processed by the disk diffusion method. Genes involved in extended spectrum beta-lactamases (BLEE), quinolones and virulence were determined by PCR.</p><p><strong>Results.: </strong>All samples exceeded the acceptable limits established in the Environmental Quality Standards for vegetable irrigation. Of the 94 isolates, 72.3% showed resistance to at least one antibiotic, 24.5% were multidrug resistant (MDR) and 2.1% were extremely resistant. The highest percentages of resistance were observed for ampicillin-sulbactam (57.1%), nalidixic acid (50%), trimethoprim-sulfamethoxazole (35.5%) and ciprofloxacin (20.4%). Among the isolates, 3.2% had a BLEE phenotype related to the bla CTX-M-15 gene. qnrB (20.4%) was the most frequent transferable mechanism of resistance to quinolones, and 2.04% had qnrS. It was estimated that 5.3% were diarrheagenic E. coli and of these, 60% were enterotoxigenic E. coli, 20% were enteropathogenic E. coli and 20% were enteroaggregative E. coli.</p><p><strong>Conclusions.: </strong>The results show the existence of diarrheogenic pathotypes in the water used for irrigation of fresh produce and highlight the presence of BLEE- and MDR-producing E. coli, demonstrating the role played by irrigation water in the dissemination of resistance genes in Peru.</p><p><p>Motivation for the study. Aquatic systems, including irrigation water, have been identified as reservoirs of antimicrobial resistance, with few studies in Peru on the presence of Escherichia coli and their levels of virulence and antimicrobial resistance. Main findings. Our results show the presence of E. coli above the established standard for vegetable irrigation water, some with very high levels of antimicrobial resistance. Implications. The presence of ESBL-producing strains of extended-spectrum beta-lactamases and multidrug-resistant E. coli in irrigation water could contribute to the dissemination of resistance genes in Peru, posing a significant threat to public health.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 2","pages":"114-120"},"PeriodicalIF":0.0,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perinatal mortality in the municipality of Panchimalco, San Salvador: a case series. 圣萨尔瓦多潘奇马尔科市的围产期死亡率:病例系列。
Q3 Medicine Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.13335
Evelyn Castellanos-Flores

Perinatal mortality is an indicator that reflects the impact of maternal and infant care in a country. This study presents nine cases of perinatal mortality that occurred in the municipality of Panchimalco, El Salvador. The information was obtained from audit reports. The mothers of the deceased infants were aged between 17 and 43 years, did not use contraceptive methods, had incomplete prenatal controls and averaged a gestational age of 31 weeks. Three deliveries were attended in the community. Most perinatal deaths occurred before delivery due to unknown causes, and live births were preterm. We identified factors such as deficits in comprehensive care for women. Further studies are needed to determine the main factors influencing perinatal deaths in El Salvador. Motivation for the study. It is necessary to understand the maternal and infant characteristics of perinatal deaths. Additionally, it is required to generate evidence that contributes to a better understanding of these events. Main findings. Nine cases of perinatal deaths with maternal-fetal risk characteristics were identified. Most deaths occurred before delivery, with prematurity predominating in the neonates. Implications. Understanding the maternal and infant characteristics of perinatal deaths is essential for developing preventive strategies aimed at reducing risk factors related to perinatal mortality.

围产期死亡率是反映一个国家母婴护理影响的指标。本研究介绍了发生在萨尔瓦多潘奇马尔科市的九例围产期死亡病例。信息来自审计报告。死亡婴儿的母亲年龄在 17 至 43 岁之间,未采取避孕措施,产前检查不完整,平均孕周为 31 周。有三例分娩是在社区进行的。大多数围产期死亡发生在分娩前,原因不明,活产婴儿均为早产儿。我们发现了产妇缺乏全面护理等因素。要确定影响萨尔瓦多围产期死亡的主要因素,还需要进一步研究。研究动机。有必要了解围产期死亡产妇和婴儿的特征。此外,还需要提供有助于更好地了解这些事件的证据。主要研究结果。共发现 9 例具有母婴风险特征的围产期死亡病例。大多数死亡发生在分娩前,新生儿以早产为主。意义。了解围产期死亡的母婴特征对于制定旨在减少围产期死亡相关风险因素的预防策略至关重要。
{"title":"Perinatal mortality in the municipality of Panchimalco, San Salvador: a case series.","authors":"Evelyn Castellanos-Flores","doi":"10.17843/rpmesp.2024.411.13335","DOIUrl":"10.17843/rpmesp.2024.411.13335","url":null,"abstract":"<p><p>Perinatal mortality is an indicator that reflects the impact of maternal and infant care in a country. This study presents nine cases of perinatal mortality that occurred in the municipality of Panchimalco, El Salvador. The information was obtained from audit reports. The mothers of the deceased infants were aged between 17 and 43 years, did not use contraceptive methods, had incomplete prenatal controls and averaged a gestational age of 31 weeks. Three deliveries were attended in the community. Most perinatal deaths occurred before delivery due to unknown causes, and live births were preterm. We identified factors such as deficits in comprehensive care for women. Further studies are needed to determine the main factors influencing perinatal deaths in El Salvador. Motivation for the study. It is necessary to understand the maternal and infant characteristics of perinatal deaths. Additionally, it is required to generate evidence that contributes to a better understanding of these events. Main findings. Nine cases of perinatal deaths with maternal-fetal risk characteristics were identified. Most deaths occurred before delivery, with prematurity predominating in the neonates. Implications. Understanding the maternal and infant characteristics of perinatal deaths is essential for developing preventive strategies aimed at reducing risk factors related to perinatal mortality.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"83-88"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with the consumption of medicinal plants for the prevention of COVID-19 in peruvian population: a cross-sectional study. 秘鲁人食用药用植物预防 COVID-19 的相关因素:一项横断面研究。
Q3 Medicine Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.13265
Fabricio Ccami-Bernal, Cristhian Rojas-Miliano, David R Soriano-Moreno, Daniel Fernández-Guzmán, Carlos Quispe-Vicuña, Enrique A Hernández-Bustamante, Elvira G Zamora-Huaringa, Wendy Nieto-Gutiérrez

Objectives.: Motivation for the study. No study conclusively recommends the use of medicinal plants to treat COVID-19 symptoms, and their indiscriminate use may present health risks. Main findings. Sixty percent of participants consumed medicinal plants to prevent COVID-19. This was particularly true for those living in the Peruvian highlands and individuals with family members diagnosed or deceased from COVID-19, who perceive a higher risk of infection and use medications or chlorine dioxide as preventive measures. Implications. Communication strategies emphasizing validated preventive practices and educating about the risks of consuming medicinal plants should be tailored to the predominant characteristics of the consumer. Determine the factors associated with the consumption of medicinal plants as a preventive measure against COVID-19 in the Peruvian population.

Materials and methods.: A population over 18 years of age, living in Peru and without a history of COVID-19 disease, was evaluated. The factors associated with the consumption of medicinal plants were evaluated using a Poisson regression model with robust variances.

Results.: Of the 3231 participants included, 84.6% were young adults (18-29 years old), 62.7% were women, and 59.7% consumed a medicinal plant to prevent COVID-19 infection. The factors associated with the consumption of medicinal plants to prevent COVID-19 infection were residing in the Peruvian highlands, having had a family member diagnosed with COVID-19, having had a family member die from COVID-19, considering their family to be at increased risk of infection, having used medications or chlorine dioxide to prevent COVID-19, having medical information as the main source of information about COVID-19, thinking that medicinal plants are effective in preventing COVID-19 disease, or not being informed about their effectiveness.

Conclusion.: Sixty percent of the participants reported having consumed a medicinal plant to prevent COVID-19. Authorities must apply communication strategies about the implications of consuming medicinal plants, prioritizing population groups with higher consumption patterns.

目标研究动机。没有研究明确建议使用药用植物来治疗 COVID-19 症状,滥用药用植物可能会带来健康风险。主要发现。60%的参与者食用药用植物来预防 COVID-19。尤其是那些生活在秘鲁高原地区的人以及有家庭成员被诊断出感染 COVID-19 或已故的人,他们认为感染的风险更高,因此使用药物或二氧化氯作为预防措施。影响。应根据消费者的主要特征制定宣传策略,强调有效的预防措施并教育人们食用药用植物的风险。确定秘鲁人食用药用植物作为预防 COVID-19 的措施的相关因素:对居住在秘鲁且无 COVID-19 疾病史的 18 岁以上人群进行了评估。采用稳健方差泊松回归模型对与药用植物消费相关的因素进行了评估:在 3231 名参与者中,84.6% 为青壮年(18-29 岁),62.7% 为女性,59.7% 食用药用植物以预防 COVID-19 感染。与食用药用植物预防 COVID-19 感染相关的因素包括:居住在秘鲁高原地区、家庭成员曾被诊断患有 COVID-19、家庭成员曾死于 COVID-19、认为家人感染 COVID-19 的风险增加、曾使用药物或二氧化氯预防 COVID-19、医疗信息是 COVID-19 的主要信息来源、认为药用植物能有效预防 COVID-19 疾病或不了解药用植物的功效:60%的参与者表示曾食用药用植物来预防 COVID-19。有关当局必须采取宣传策略,让人们了解食用药用植物的意义,并优先考虑食用药用植物较多的人群。
{"title":"Factors associated with the consumption of medicinal plants for the prevention of COVID-19 in peruvian population: a cross-sectional study.","authors":"Fabricio Ccami-Bernal, Cristhian Rojas-Miliano, David R Soriano-Moreno, Daniel Fernández-Guzmán, Carlos Quispe-Vicuña, Enrique A Hernández-Bustamante, Elvira G Zamora-Huaringa, Wendy Nieto-Gutiérrez","doi":"10.17843/rpmesp.2024.411.13265","DOIUrl":"10.17843/rpmesp.2024.411.13265","url":null,"abstract":"<p><strong>Objectives.: </strong>Motivation for the study. No study conclusively recommends the use of medicinal plants to treat COVID-19 symptoms, and their indiscriminate use may present health risks. Main findings. Sixty percent of participants consumed medicinal plants to prevent COVID-19. This was particularly true for those living in the Peruvian highlands and individuals with family members diagnosed or deceased from COVID-19, who perceive a higher risk of infection and use medications or chlorine dioxide as preventive measures. Implications. Communication strategies emphasizing validated preventive practices and educating about the risks of consuming medicinal plants should be tailored to the predominant characteristics of the consumer. Determine the factors associated with the consumption of medicinal plants as a preventive measure against COVID-19 in the Peruvian population.</p><p><strong>Materials and methods.: </strong>A population over 18 years of age, living in Peru and without a history of COVID-19 disease, was evaluated. The factors associated with the consumption of medicinal plants were evaluated using a Poisson regression model with robust variances.</p><p><strong>Results.: </strong>Of the 3231 participants included, 84.6% were young adults (18-29 years old), 62.7% were women, and 59.7% consumed a medicinal plant to prevent COVID-19 infection. The factors associated with the consumption of medicinal plants to prevent COVID-19 infection were residing in the Peruvian highlands, having had a family member diagnosed with COVID-19, having had a family member die from COVID-19, considering their family to be at increased risk of infection, having used medications or chlorine dioxide to prevent COVID-19, having medical information as the main source of information about COVID-19, thinking that medicinal plants are effective in preventing COVID-19 disease, or not being informed about their effectiveness.</p><p><strong>Conclusion.: </strong>Sixty percent of the participants reported having consumed a medicinal plant to prevent COVID-19. Authorities must apply communication strategies about the implications of consuming medicinal plants, prioritizing population groups with higher consumption patterns.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"37-45"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefits of being part of a support group for caregivers of children with multiple disabilities: a qualitative study. 参加多重残疾儿童照顾者支持小组的益处:一项定性研究。
Q3 Medicine Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.13218
María Elena Rodríguez-Vélez, Claudia Patricia Cantillo-Medina, Alix Yaneth Perdomo-Romero

Objective: Motivation for the study. Filling a knowledge gap regarding support groups for caregivers of children with multiple disabilities. Main findings. Support groups are valuable spaces for social support and learning for caregivers of children with multiple disabilities. They facilitate resilience and coping strategies following the birth of a child with multiple disabilities. They promote the participation and empowerment of caregivers of children with multiple disabilities to address access barriers and advocate for the fundamental rights of children. Implications. It is important to promote and support support groups for caregivers of children with multiple disabilities. To explore the perceived benefits of participating in a support group of caregivers of children with multiple disabilities.

Materials and methods.: A qualitative study with a focused ethnographic approach was conducted from October 2022 to February 2023, in which we applied convenience sampling. We included 20 caregivers of children with multiple disabilities. Information was collected through participant observation, focus groups, and semi-structured interviews. Thematic analysis was performed by applying Braun and Clark's proposals.

Results.: The emerging themes were: social support network: integrating, informing, and helping each other; learning space: learning to take care and to take care of oneself; promoting empowerment: identifying and facing access barriers.

Conclusions.: We found that the support group functions as a social support network provides information, reduces uncertainty, and facilitates coping and resilience after the birth and upbringing of a child with multiple disabilities. It is a space where one learns to care for and take care of oneself and where empowerment for the defense of the rights of children with disabilities is promoted.

目标:研究动机。填补有关多重残疾儿童照顾者支持小组的知识空白。主要发现。支持小组是多重残疾儿童照顾者获得社会支持和学习的宝贵空间。它们促进了多重残疾儿童出生后的恢复能力和应对策略。它们促进了多重残疾儿童照护者的参与并增强了他们的能力,使他们能够解决获得服务的障碍并倡导儿童的基本权利。影响。推广和支持多重残疾儿童照顾者支持小组非常重要。探讨多重残疾儿童照顾者参加支持小组的益处:2022 年 10 月至 2023 年 2 月,我们采用便利抽样法,开展了一项以重点人种学方法为基础的定性研究。我们纳入了 20 名多重残疾儿童的照顾者。我们通过参与观察、焦点小组和半结构化访谈收集信息。我们采用布劳恩和克拉克的建议进行了主题分析:新出现的主题是:社会支持网络:相互融合、相互告知和相互帮助;学习空间:学会照顾和照顾自己;促进赋权:识别和面对获取障碍:我们发现,支持小组作为一个社会支持网络,可以提供信息,减少不确定性,促进多重残疾儿童出生和成长后的应对和恢复能力。在这个空间里,人们学会了关心和照顾自己,并增强了捍卫残疾儿童权利的能力。
{"title":"Benefits of being part of a support group for caregivers of children with multiple disabilities: a qualitative study.","authors":"María Elena Rodríguez-Vélez, Claudia Patricia Cantillo-Medina, Alix Yaneth Perdomo-Romero","doi":"10.17843/rpmesp.2024.411.13218","DOIUrl":"10.17843/rpmesp.2024.411.13218","url":null,"abstract":"<p><strong>Objective: </strong>Motivation for the study. Filling a knowledge gap regarding support groups for caregivers of children with multiple disabilities. Main findings. Support groups are valuable spaces for social support and learning for caregivers of children with multiple disabilities. They facilitate resilience and coping strategies following the birth of a child with multiple disabilities. They promote the participation and empowerment of caregivers of children with multiple disabilities to address access barriers and advocate for the fundamental rights of children. Implications. It is important to promote and support support groups for caregivers of children with multiple disabilities. To explore the perceived benefits of participating in a support group of caregivers of children with multiple disabilities.</p><p><strong>Materials and methods.: </strong>A qualitative study with a focused ethnographic approach was conducted from October 2022 to February 2023, in which we applied convenience sampling. We included 20 caregivers of children with multiple disabilities. Information was collected through participant observation, focus groups, and semi-structured interviews. Thematic analysis was performed by applying Braun and Clark's proposals.</p><p><strong>Results.: </strong>The emerging themes were: social support network: integrating, informing, and helping each other; learning space: learning to take care and to take care of oneself; promoting empowerment: identifying and facing access barriers.</p><p><strong>Conclusions.: </strong>We found that the support group functions as a social support network provides information, reduces uncertainty, and facilitates coping and resilience after the birth and upbringing of a child with multiple disabilities. It is a space where one learns to care for and take care of oneself and where empowerment for the defense of the rights of children with disabilities is promoted.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"54-61"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metformin treatment prevents experimental metabolic syndrome-induced femoral bone marrow adiposity in rats. 二甲双胍治疗可预防实验性代谢综合征诱发的大鼠股骨髓肥大。
Q3 Medicine Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.13333
Siro Lasalvia, Claudia Sedlinsky, León Schurman, Antonio Desmond McCarthy, Nahuel Ezequiel Wanionok

Objective.: Motivation for the study. Most research supports a negative association between metabolic syndrome and bone health, although there is an overall lack of consensus. Therefore, there is a need for research in this area to develop a better understanding. Main findings. Metabolic syndrome induced by a fructose-rich diet increases the adipogenic predisposition of bone marrow progenitor cells and femoral medullary adiposity in rats. Furthermore, this can be partially prevented by co-treatment with metformin. Implications. Experimental metabolic syndrome has negative effects on bone tissue and can be prevented by oral treatment with metformin as a normoglycemic drug. To determine the effect of metformin (MET) treatment on adipogenic predisposition of bone marrow progenitor cells (BMPC), bone marrow adiposity and bone biomechanical properties.

Materials and methods.: 20 young adult male Wistar rats were sorted into four groups. Each of the groups received the following in drinking water: 100% water (C); 20% fructose (F); metformin 100 mg/kg wt/day (M); or fructose plus metformin (FM). After five weeks the animals were sacrificed. Both humeri were dissected to obtain BMPC, and both femurs were dissected to evaluate medullary adiposity (histomorphometry) and biomechanical properties (3-point bending). BMPC were cultured in vitro in adipogenic medium to evaluate RUNX2, PPAR-γ and RAGE expression by RT-PCR, lipase activity and triglyceride accumulation.

Results.: The fructose-rich diet (group F) caused an increase in both triglycerides in vitro, and medullary adiposity in vivo; being partially or totally prevented by co-treatment with metformin (group FM). No differences were found in femoral biomechanical tests in vivo, nor in lipase activity and RUNX2/PPAR-γ ratio in vitro. DRF increased RAGE expression in BMPC, being prevented by co-treatment with MET.

Conclusions.: Metabolic syndrome induced by a fructose-rich diet increases femoral medullary adiposity and, in part, the adipogenic predisposition of BMPC. In turn, this can be totally or partially prevented by oral co-treatment with MET.

目标研究动机。大多数研究支持代谢综合征与骨骼健康之间存在负相关,但总体上缺乏共识。因此,有必要对这一领域进行研究,以加深理解。主要研究结果。富含果糖的饮食会诱发代谢综合征,增加大鼠骨髓祖细胞的致脂肪倾向性和股骨髓髓质脂肪含量。此外,与二甲双胍联合治疗可部分防止这种情况。影响。实验性代谢综合征对骨组织有负面影响,而二甲双胍作为一种正常血糖药物,可以通过口服治疗来预防。材料和方法:20 只年轻的成年雄性 Wistar 大鼠:将 20 只年轻的成年雄性 Wistar 大鼠分为四组。每组在饮用水中加入以下成分:100% 水(C);20% 果糖(F);二甲双胍 100 毫克/千克湿重/天(M);或果糖加二甲双胍(FM)。五周后,动物被处死。解剖双侧肱骨以获得 BMPC,解剖双侧股骨以评估髓质脂肪(组织形态学)和生物力学特性(三点弯曲)。在脂肪生成培养基中体外培养 BMPC,通过 RT-PCR 评估 RUNX2、PPAR-γ 和 RAGE 的表达、脂肪酶活性和甘油三酯的积累:结果:富含果糖的饮食(F组)在体外导致甘油三酯增加,在体内导致髓质脂肪增加;与二甲双胍联合治疗(FM组)可部分或完全防止甘油三酯增加。体内股骨生物力学测试、体外脂肪酶活性和 RUNX2/PPAR-γ 比率均未发现差异。DRF 增加了 BMPC 中 RAGE 的表达,而与 MET 联合处理则可防止这种情况的发生:结论:富含果糖的饮食会诱发代谢综合征,增加股骨髓脂肪含量,并在一定程度上增加 BMPC 的致脂倾向。反过来,口服 MET 可完全或部分防止这种情况的发生。
{"title":"Metformin treatment prevents experimental metabolic syndrome-induced femoral bone marrow adiposity in rats.","authors":"Siro Lasalvia, Claudia Sedlinsky, León Schurman, Antonio Desmond McCarthy, Nahuel Ezequiel Wanionok","doi":"10.17843/rpmesp.2024.411.13333","DOIUrl":"10.17843/rpmesp.2024.411.13333","url":null,"abstract":"<p><strong>Objective.: </strong>Motivation for the study. Most research supports a negative association between metabolic syndrome and bone health, although there is an overall lack of consensus. Therefore, there is a need for research in this area to develop a better understanding. Main findings. Metabolic syndrome induced by a fructose-rich diet increases the adipogenic predisposition of bone marrow progenitor cells and femoral medullary adiposity in rats. Furthermore, this can be partially prevented by co-treatment with metformin. Implications. Experimental metabolic syndrome has negative effects on bone tissue and can be prevented by oral treatment with metformin as a normoglycemic drug. To determine the effect of metformin (MET) treatment on adipogenic predisposition of bone marrow progenitor cells (BMPC), bone marrow adiposity and bone biomechanical properties.</p><p><strong>Materials and methods.: </strong>20 young adult male Wistar rats were sorted into four groups. Each of the groups received the following in drinking water: 100% water (C); 20% fructose (F); metformin 100 mg/kg wt/day (M); or fructose plus metformin (FM). After five weeks the animals were sacrificed. Both humeri were dissected to obtain BMPC, and both femurs were dissected to evaluate medullary adiposity (histomorphometry) and biomechanical properties (3-point bending). BMPC were cultured in vitro in adipogenic medium to evaluate RUNX2, PPAR-γ and RAGE expression by RT-PCR, lipase activity and triglyceride accumulation.</p><p><strong>Results.: </strong>The fructose-rich diet (group F) caused an increase in both triglycerides in vitro, and medullary adiposity in vivo; being partially or totally prevented by co-treatment with metformin (group FM). No differences were found in femoral biomechanical tests in vivo, nor in lipase activity and RUNX2/PPAR-γ ratio in vitro. DRF increased RAGE expression in BMPC, being prevented by co-treatment with MET.</p><p><strong>Conclusions.: </strong>Metabolic syndrome induced by a fructose-rich diet increases femoral medullary adiposity and, in part, the adipogenic predisposition of BMPC. In turn, this can be totally or partially prevented by oral co-treatment with MET.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"28-36"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis. 在早期或不可切除或转移性 HER-2 阳性乳腺癌中使用曲妥珠单抗-emtansine 与其他抗 HER2 方案的比较:系统综述和网络荟萃分析。
Q3 Medicine Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.13351
Agustín Ciapponi, Ariel Bardach, Carla Colaci, Federico Rodríguez Cairoli, Fernando Argento, Ernesto Korbenfeld, Sebastián García Martí

Objective.: Motivation for the study. Treatment options for HER2-positive breast cancer were evaluated, focusing on the efficacy and safety of trastuzumab-emtansine (T-DM1) compared to other anti-HER2 therapies. Main findings. Trastuzumab-deruxtecan (T-DXd) and PyroCap emerged as promising alternatives, showing substantial improvements in progression-free survival for locally advanced or metastatic breast cancer. T-DM1 showed superior efficacy to the other treatments. Implications. Our findings could inform healthcare decision-making processes to optimize strategies for HER2-positive breast cancer, and potentially improve health outcomes and quality of life. We aimed to study the efficacy and safety of trastuzumab-emtansine (T-DM1) versus other anti-HER2 therapies in HER2+ breast cancer (BC).

Materials and methods.: We performed a network meta-analysis (NMA) of randomized controlled trials (RCTs). Our study focused on patients undergoing treatment for unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (mBC), which included regimens involving trastuzumab and taxanes. Additionally, we considered cases within the first 6 months of treatment for HER2+ early breast cancer (EBC).

Results.: A total of 23 RCTs and 41 reports were included in our analysis. LABC and mBC showed no statistically significant difference in any of the comparisons of T-DM1 versus the other anti-HER2+ therapies. When assessing progression-free survival (PFS), trastuzumab-deruxtecan (T-DXd) and PyroCap demonstrated greater efficacy compared to other treatments (Hazard Ratio [HR]: 3.57; 95% confidence interval [CI]: 2.75-4.63 and HR: 1.82; 95% CI: 1.35-2.44; respectively), while T-DM1 alone exhibited superior effectiveness compared to LapCap (HR: 0.65; 95% CI: 0.55-0.77), TrasCap (HR: 0.65; 95% CI: 0.46-0.91), LapCapCitu (HR: 0.60; 95% CI: 0.33-1.10), Nera (HR: 0.55; 95% CI: 0.39-0.77), and Cap (HR: 0.37; 95% CI: 0.28-0.49).

Conclusions.: NMA allows a ranking based on the comparative efficacy and safety among the interventions available. Although superior to other schemes, T-DM1 showed a lower efficacy performance in PFS and overall response rate and a trend towards worse overall survival than T-DXd.

目标研究动机。对HER2阳性乳腺癌的治疗方案进行评估,重点是曲妥珠单抗-依单抗(T-DM1)与其他抗HER2疗法相比的疗效和安全性。主要研究结果曲妥珠单抗-德鲁司坦(T-DXd)和PyroCap是很有前景的替代疗法,它们大大改善了局部晚期或转移性乳腺癌患者的无进展生存期。T-DM1的疗效优于其他疗法。意义。我们的研究结果可为医疗决策过程提供信息,以优化 HER2 阳性乳腺癌的治疗策略,并有可能改善健康状况和生活质量。我们旨在研究曲妥珠单抗-伊坦信(T-DM1)与其他抗HER2疗法在HER2+乳腺癌(BC)中的疗效和安全性:我们对随机对照试验(RCT)进行了网络荟萃分析(NMA)。我们的研究侧重于接受不可切除的局部晚期乳腺癌(LABC)或转移性乳腺癌(mBC)治疗的患者,其中包括曲妥珠单抗和紫杉类药物治疗方案。此外,我们还考虑了HER2+早期乳腺癌(EBC)治疗头6个月内的病例:共有 23 项 RCT 和 41 份报告纳入了我们的分析。在T-DM1与其他抗HER2+疗法的比较中,LABC和mBC在统计学上没有明显差异。在评估无进展生存期(PFS)时,与其他疗法相比,曲妥珠单抗-德鲁替康(T-DXd)和PyroCap的疗效更好(危险比[HR]:分别为3.57;95%置信区间[CI]:2.75-4.63和HR:1.82;95% CI:1.35-2.44),而单用T-DM1与LapCap相比疗效更优(HR:0.65;95% CI:0.55-0.77)、TrasCap(HR:0.65;95% CI:0.46-0.91)、LapCapCitu(HR:0.60;95% CI:0.33-1.10)、Nera(HR:0.55;95% CI:0.39-0.77)和Cap(HR:0.37;95% CI:0.28-0.49)相比,单用T-DM1表现出更高的有效性:NMA 可以根据现有干预措施的疗效和安全性进行排序。尽管T-DM1优于其他方案,但其在PFS和总体反应率方面的疗效表现低于T-DXd,总体生存率也有低于T-DXd的趋势。
{"title":"Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis.","authors":"Agustín Ciapponi, Ariel Bardach, Carla Colaci, Federico Rodríguez Cairoli, Fernando Argento, Ernesto Korbenfeld, Sebastián García Martí","doi":"10.17843/rpmesp.2024.411.13351","DOIUrl":"10.17843/rpmesp.2024.411.13351","url":null,"abstract":"<p><strong>Objective.: </strong>Motivation for the study. Treatment options for HER2-positive breast cancer were evaluated, focusing on the efficacy and safety of trastuzumab-emtansine (T-DM1) compared to other anti-HER2 therapies. Main findings. Trastuzumab-deruxtecan (T-DXd) and PyroCap emerged as promising alternatives, showing substantial improvements in progression-free survival for locally advanced or metastatic breast cancer. T-DM1 showed superior efficacy to the other treatments. Implications. Our findings could inform healthcare decision-making processes to optimize strategies for HER2-positive breast cancer, and potentially improve health outcomes and quality of life. We aimed to study the efficacy and safety of trastuzumab-emtansine (T-DM1) versus other anti-HER2 therapies in HER2+ breast cancer (BC).</p><p><strong>Materials and methods.: </strong>We performed a network meta-analysis (NMA) of randomized controlled trials (RCTs). Our study focused on patients undergoing treatment for unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (mBC), which included regimens involving trastuzumab and taxanes. Additionally, we considered cases within the first 6 months of treatment for HER2+ early breast cancer (EBC).</p><p><strong>Results.: </strong>A total of 23 RCTs and 41 reports were included in our analysis. LABC and mBC showed no statistically significant difference in any of the comparisons of T-DM1 versus the other anti-HER2+ therapies. When assessing progression-free survival (PFS), trastuzumab-deruxtecan (T-DXd) and PyroCap demonstrated greater efficacy compared to other treatments (Hazard Ratio [HR]: 3.57; 95% confidence interval [CI]: 2.75-4.63 and HR: 1.82; 95% CI: 1.35-2.44; respectively), while T-DM1 alone exhibited superior effectiveness compared to LapCap (HR: 0.65; 95% CI: 0.55-0.77), TrasCap (HR: 0.65; 95% CI: 0.46-0.91), LapCapCitu (HR: 0.60; 95% CI: 0.33-1.10), Nera (HR: 0.55; 95% CI: 0.39-0.77), and Cap (HR: 0.37; 95% CI: 0.28-0.49).</p><p><strong>Conclusions.: </strong>NMA allows a ranking based on the comparative efficacy and safety among the interventions available. Although superior to other schemes, T-DM1 showed a lower efficacy performance in PFS and overall response rate and a trend towards worse overall survival than T-DXd.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"7-18"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141160200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of children with autism spectrum disorder in pediatric rehabilitation at a referral hospital in Peru. 秘鲁一家转诊医院儿科康复中心自闭症谱系障碍儿童的特征。
Q3 Medicine Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.13285
Roger De la Cerna-Luna, Daniel Fernandez-Guzman, Marilia Baquerizo-Sedano, Stephanie Cabala-Olazabal, Alvaro Taype-Rondan

Objective.: Motivation for the study. Despite the prevalence of ASD, research in the field of Physical Medicine and Rehabilitation is scarce in Peru. Main findings. Of 120 children with a previous diagnosis of ASD, only 9.8% received inclusive education. The median age at diagnosis was 3.83 years. We also found that 78.4% had no disability certificate and 77.5% had incomplete psychological evaluation. The median time since the last physical, occupational, and speech therapy sessions was 3 months, 8 months, and 3.5 months, respectively. Implications. These findings highlight the need to enhance early diagnosis, inclusive education, and evaluation and subsequent certification of disability, as well as to establish more timely interventions. Autism spectrum disorder (ASD) is characterized by developmental disorders, difficulties in social interaction and communication, and restrictive and repetitive patterns of behavior. Despite its high prevalence, few studies have been conducted in rehabilitation settings. This study aimed to describe the characteristics of children with ASD from the Pediatric Rehabilitation Service of the Rebagliati Hospital (SRP-HNERM).

Materials and methods.: Cross-sectional descriptive study. We reviewed the medical records of children under 14 years of age previously diagnosed with ASD from the SRP-HNERM during 2022.

Results.: A total of 120 children with ASD were evaluated. The median age was 5 years. Most received regular education, but it was inclusive only for 9.8%. The mean age at diagnosis was 3.83 years. We found that 78.4% had no disability certificate and 77.5% of the participants had incomplete psychological evaluation. The median time since the last physical, occupational and speech therapy sessions was 3, 8 and 3.5 months respectively.

Conclusion.: The mean age at diagnosis of ASD was older than three years, and more than 75% of the patients had neither a disability certificate nor a complete psychological evaluation. The median time since the last rehabilitation therapy sessions was three months or more. Our findings highlight the need to improve early diagnosis, inclusive education and evaluation and subsequent certification of disability, as well as to establish timely interventions.

目标研究动机。尽管自闭症的发病率很高,但秘鲁在物理医学和康复领域的研究却很少。主要研究结果。在 120 名曾被诊断为 ASD 的儿童中,只有 9.8% 接受了全纳教育。诊断年龄的中位数为 3.83 岁。我们还发现,78.4%的儿童没有残疾证明,77.5%的儿童心理评估不完整。距离上一次物理治疗、职业治疗和言语治疗的中位时间分别为 3 个月、8 个月和 3.5 个月。意义。这些研究结果突显了加强早期诊断、全纳教育、评估和后续残疾认证以及制定更及时干预措施的必要性。自闭症谱系障碍(ASD)的特点是发育障碍、社会交往和沟通困难以及限制性和重复性行为模式。尽管其发病率很高,但在康复环境中进行的研究却很少。本研究旨在描述雷巴格利亚蒂医院(SRP-HNERM)儿科康复服务机构中患有自闭症儿童的特征:横断面描述性研究。我们查阅了2022年期间SRP-HNERM曾诊断出患有自闭症的14岁以下儿童的病历:共有 120 名 ASD 儿童接受了评估。中位年龄为 5 岁。大多数儿童接受正规教育,但只有 9.8% 的儿童接受全纳教育。确诊时的平均年龄为 3.83 岁。我们发现,78.4%的患者没有残疾证明,77.5%的患者心理评估不完整。最后一次物理治疗、职业治疗和言语治疗的中位时间分别为 3 个月、8 个月和 3.5 个月:诊断为自闭症的平均年龄超过 3 岁,超过 75% 的患者既没有残疾证,也没有完整的心理评估。距离上一次康复治疗的时间中位数为三个月或更长。我们的研究结果突出表明,有必要改进早期诊断、全纳教育和评估以及随后的残疾认证,并制定及时的干预措施。
{"title":"Characteristics of children with autism spectrum disorder in pediatric rehabilitation at a referral hospital in Peru.","authors":"Roger De la Cerna-Luna, Daniel Fernandez-Guzman, Marilia Baquerizo-Sedano, Stephanie Cabala-Olazabal, Alvaro Taype-Rondan","doi":"10.17843/rpmesp.2024.411.13285","DOIUrl":"10.17843/rpmesp.2024.411.13285","url":null,"abstract":"<p><strong>Objective.: </strong>Motivation for the study. Despite the prevalence of ASD, research in the field of Physical Medicine and Rehabilitation is scarce in Peru. Main findings. Of 120 children with a previous diagnosis of ASD, only 9.8% received inclusive education. The median age at diagnosis was 3.83 years. We also found that 78.4% had no disability certificate and 77.5% had incomplete psychological evaluation. The median time since the last physical, occupational, and speech therapy sessions was 3 months, 8 months, and 3.5 months, respectively. Implications. These findings highlight the need to enhance early diagnosis, inclusive education, and evaluation and subsequent certification of disability, as well as to establish more timely interventions. Autism spectrum disorder (ASD) is characterized by developmental disorders, difficulties in social interaction and communication, and restrictive and repetitive patterns of behavior. Despite its high prevalence, few studies have been conducted in rehabilitation settings. This study aimed to describe the characteristics of children with ASD from the Pediatric Rehabilitation Service of the Rebagliati Hospital (SRP-HNERM).</p><p><strong>Materials and methods.: </strong>Cross-sectional descriptive study. We reviewed the medical records of children under 14 years of age previously diagnosed with ASD from the SRP-HNERM during 2022.</p><p><strong>Results.: </strong>A total of 120 children with ASD were evaluated. The median age was 5 years. Most received regular education, but it was inclusive only for 9.8%. The mean age at diagnosis was 3.83 years. We found that 78.4% had no disability certificate and 77.5% of the participants had incomplete psychological evaluation. The median time since the last physical, occupational and speech therapy sessions was 3, 8 and 3.5 months respectively.</p><p><strong>Conclusion.: </strong>The mean age at diagnosis of ASD was older than three years, and more than 75% of the patients had neither a disability certificate nor a complete psychological evaluation. The median time since the last rehabilitation therapy sessions was three months or more. Our findings highlight the need to improve early diagnosis, inclusive education and evaluation and subsequent certification of disability, as well as to establish timely interventions.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"19-27"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growing threat of emerging and reemerging diseases: arboviruses and vector-borne diseases in the Americas. 新出现和再次出现的疾病的威胁与日俱增:美洲的虫媒病毒和病媒传染病。
Q3 Medicine Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.13805
César Cabezas, Pedro F C Vasconcelos
{"title":"Growing threat of emerging and reemerging diseases: arboviruses and vector-borne diseases in the Americas.","authors":"César Cabezas, Pedro F C Vasconcelos","doi":"10.17843/rpmesp.2024.411.13805","DOIUrl":"10.17843/rpmesp.2024.411.13805","url":null,"abstract":"","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"4-6"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative evaluation of dissolution profiles of the generic drug lamivudine 150 mg tablet marketed in Peru vs. the innovative Epivir. 秘鲁市场上销售的非专利药拉米夫定 150 毫克片剂与创新药 Epivir 的溶解曲线比较评估。
Q3 Medicine Pub Date : 2024-05-27 DOI: 10.17843/rpmesp.2024.411.12821
Malena Castañeda-Alarcón, Encarna García-Montoya, Javier Rodríguez-Calzado, María Flores-Rodríguez, Miguel Grande-Ortíz, Luis Moreno-Exebio

Lamivudine is one of the most prescribed drugs in the world, and is used to treat human immunodeficiency and hepatitis B. This study aimed to evaluate the quality attributes and compare the dissolution profiles of two batches (A and B) of generic lamivudine 150 mg tablets with the innovator drug Epivir 150 mg tablets. We conducted an analytical, experimental, cross-sectional study, and used a spectrophotometric method at a wavelength of maximum absorption (λ) corresponding to 270 nm, to measure the percentage of dissolved drug. The study evaluated identification, content, dissolution and mass uniformity. Apparatus 2 USP (Paddle) 75 rpm, 900 mL of dissolution medium (37 ± 0.5 °C) was used in three dissolution media: pH 1.2; 4.5 and 6.8. Samples of 5 mL were obtained at 5, 10, 15, 20 and 30 min. Both batches of generic lamivudine (A and B) were found to have the same dissolution kinetic profile as the innovator drug. Both formulations met the criteria of very fast dissolving (85% dissolved in 15 min), and fast dissolving (85% dissolved in 30 min) drugs. Therefore, it was not necessary to calculate the similarity factor. We concluded that generic drugs A and B are in vitro equivalents to the innovator drug Epivir. Motivation for the study. To evaluate the quality of antiretroviral drugs used in the treatment of HIV dispensed in the HAART Program of the Ministry of Health of Peru. Main findings. Two batches of generic lamivudine drugs were found to achieve a dissolution rate greater than 85% at 15 min, being equivalent in vitro to the reference product Epivir. Implications. There is a need to apply the current regulations regarding equivalence between drugs by the regulatory authority prior to their authorization and to include dissolution profile tests as a requirement in public drug purchases, especially in national strategies (HIV, TB, etc.), in order to ensure quality products for the population.

拉米夫定是世界上处方量最大的药物之一,用于治疗人类免疫缺陷和乙型肝炎。本研究旨在评估两个批次(A 和 B)拉米夫定 150 毫克仿制药片与创新药 Epivir 150 毫克片剂的质量属性并比较其溶解曲线。我们进行了一项分析、实验和横断面研究,并使用分光光度法在最大吸收波长 (λ) 相当于 270 纳米的波长上测量溶解药物的百分比。研究评估了鉴定、含量、溶解度和质量均匀性。仪器 2 USP(桨式)75 转/分,900 毫升溶解介质(37 ± 0.5 °C)用于三种溶解介质:pH 值 1.2、4.5 和 6.8。分别在 5、10、15、20 和 30 分钟取 5 mL 样品。结果表明,两个批次的拉米夫定仿制药(A 和 B)与创新药具有相同的溶解动力学特征。两种制剂均符合极速溶解(15 分钟内溶解 85%)和快速溶解(30 分钟内溶解 85%)药物的标准。因此,没有必要计算相似系数。我们的结论是,仿制药 A 和 B 与创新药 Epivir 具有体外等效性。研究动机评估秘鲁卫生部 HAART 计划中用于治疗 HIV 的抗逆转录病毒药物的质量。主要发现。发现两个批次的拉米夫定非专利药在 15 分钟内的溶解度大于 85%,与参考产品 Epivir 的体外溶解度相当。影响。有必要在药品授权之前,由监管机构对药品之间的等效性实施现行规定,并将溶解度曲线测试作为公共药品采购的一项要求,特别是在国家战略(艾滋病、结核病等)中,以确保为民众提供优质产品。
{"title":"Comparative evaluation of dissolution profiles of the generic drug lamivudine 150 mg tablet marketed in Peru vs. the innovative Epivir.","authors":"Malena Castañeda-Alarcón, Encarna García-Montoya, Javier Rodríguez-Calzado, María Flores-Rodríguez, Miguel Grande-Ortíz, Luis Moreno-Exebio","doi":"10.17843/rpmesp.2024.411.12821","DOIUrl":"10.17843/rpmesp.2024.411.12821","url":null,"abstract":"<p><p>Lamivudine is one of the most prescribed drugs in the world, and is used to treat human immunodeficiency and hepatitis B. This study aimed to evaluate the quality attributes and compare the dissolution profiles of two batches (A and B) of generic lamivudine 150 mg tablets with the innovator drug Epivir 150 mg tablets. We conducted an analytical, experimental, cross-sectional study, and used a spectrophotometric method at a wavelength of maximum absorption (λ) corresponding to 270 nm, to measure the percentage of dissolved drug. The study evaluated identification, content, dissolution and mass uniformity. Apparatus 2 USP (Paddle) 75 rpm, 900 mL of dissolution medium (37 ± 0.5 °C) was used in three dissolution media: pH 1.2; 4.5 and 6.8. Samples of 5 mL were obtained at 5, 10, 15, 20 and 30 min. Both batches of generic lamivudine (A and B) were found to have the same dissolution kinetic profile as the innovator drug. Both formulations met the criteria of very fast dissolving (85% dissolved in 15 min), and fast dissolving (85% dissolved in 30 min) drugs. Therefore, it was not necessary to calculate the similarity factor. We concluded that generic drugs A and B are in vitro equivalents to the innovator drug Epivir. Motivation for the study. To evaluate the quality of antiretroviral drugs used in the treatment of HIV dispensed in the HAART Program of the Ministry of Health of Peru. Main findings. Two batches of generic lamivudine drugs were found to achieve a dissolution rate greater than 85% at 15 min, being equivalent in vitro to the reference product Epivir. Implications. There is a need to apply the current regulations regarding equivalence between drugs by the regulatory authority prior to their authorization and to include dissolution profile tests as a requirement in public drug purchases, especially in national strategies (HIV, TB, etc.), in order to ensure quality products for the population.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"69-75"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista Peruana de Medicina de Experimental y Salud Publica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1